Skip to main content

Table 9 WOMAC scales inter-group comparisons

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

  Pain Stiffness Function
  30
days
60
days
90
days
30
days
60
days
90
days
30
days
60
days
90
days
UP446 500 mgs vs.
UP446 250 mgs
NS* NS 0.038 NS NS NS NS NS NS
UP446 250 mgs vs.
CELECOXIB 200 mgs
NS NS NS NS NS NS 0.010 NS NS
UP446 500 mgs vs.
CELECOXIB 200 mgs
0.020 NS NS NS NS NS 0.015 0.043 0.039
UP446 250 mgs vs.
PLACEBO
NS NS NS 0.000 0.027 0.015 0.010 0.043 0.039
UP446 500 mgs vs.
PLACEBO
0.044 0.032 0.001 0.001 NS 0.005 0.015 0.016 0.003
CELECOXIB 200 mgs
vs. PLACEBO
NS 0.009 NS 0.023 NS NS 0.015 0.016 0.003
  1. *NS: Not statistically significant